Capricor Therapeutics, Inc.

NASDAQ:CAPR

Biotechnology

Healthcare
$8.41 -0.50%

-$0.14 today

Market cap
$487.04M
Beta
0.37
P/E (TTM)
-13.9
EPS (TTM)
-$2.00
52W Low $4.30High $40.37

Volume 4.62M

Average 1.08M

CAPR EBITDA Margin

EBITDA as a percentage of revenue.

Capricor Therapeutics, Inc.NASDAQ: CAPR

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Context

  • EBITDA Margin widened in 1 of the last 2 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2024
-175.3%
Year-over-year change
-91.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CAPR compares with its peers on the latest reported figures

CAPR Competitors Peer median
EBITDA Margin for CAPR and competitors
Company Period LTM level YoY 3-year change
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20265.7% +10.5 pp+34.3 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-49.3% -33.5 pp+8.7 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-243.2% -144.4 pp+3681.3 pp
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-2873.3% -2889.4 pp—
CAPRCapricor Therapeutics, Inc.FY2025— ——
EWTXEdgewise Therapeutics, Inc.FY2025— ——
DYNDyne Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
Peer median (excluding CAPR) -49.3%-33.5 pp+69.1 pp

Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue244.9K2.55M25.18M22.27M0
Cost of Revenue021.82M36.45M49.97M0
Gross Profit244.9K(19.27M)(11.27M)(27.7M)0
Gross Margin100.0%-755.1%-44.8%-124.4%—
Research & Development13.57M21.82M36.45M49.97M84.45M
Selling, General & Admin7.61M10.43M12.81M14.87M22.75M
Operating Expenses21.18M10.43M12.81M14.87M108.14M
Depreciation & Amortization245.7K533.13K1.07M1.43M1.89M
EBITDA(19.78M)(28.49M)(21.22M)(39.04M)(100.11M)
EBITDA Margin-8075.5%-1116.5%-84.3%-175.3%—
Operating Income(20.94M)(29.7M)(24.08M)(42.56M)(108.14M)
Operating Margin-8549.9%-1163.9%-95.6%-191.1%—
Interest Income0521.53K1.73M2.2M6.26M
Interest Expense00003.05M
Other Income / Expenses915.92K677.85K1.79M2.1M3.1M
Income Before Tax(20.02M)(29.02M)(22.29M)(40.47M)(105.04M)
Pre-Tax Margin-8175.9%-1137.4%-88.5%-181.7%—
Income Tax Expense00000
Net Income(20.02M)(29.02M)(22.29M)(40.47M)(105.04M)
Net Margin-8175.9%-1137.4%-88.5%-181.7%—
EPS (Basic)(0.87)(1.18)(0.83)(1.15)(2.26)
EPS (Diluted)(0.87)(1.18)(0.83)(1.15)(2.26)
Weighted Avg Shares23.09M24.55M26.78M35.22M46.48M
Weighted Avg Shares (Diluted)23.09M24.55M26.78M35.22M46.48M

Capricor Therapeutics, Inc.

NASDAQ:CAPR

Intrinsic Alpha fair value

Locked

Current Price

$8.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.